Table 1

Efficacy of ChAdOx1-GnGc and HAdV5-GnGc vaccines against RVF virus challenge
Vaccination regimen Number sick/Total challenged Viraemia post-challenge
(TCID50/ml)
ChAdOx1-GnGc 0/6 0
ChAdOx1-GnGc + 25μl AddaVax™ 0/6 0
ChAdOx1-GnGc + 25μg Matrix-M™ 0/6 0
HAdV5-GnGc 0/6 0
HAdV5-GnGc + 25μl AddaVax™ 0/6 0
HAdV5-GnGc + 25μg Matrix-M™ 0/6 0
Unvaccinated controls 6/6 21380

For each vaccination regimen the number of mice developing clinical signs of RVF following challenge with RVF virus is shown. Viraemia, assessed by RVF virus isolation three days post-challenge, is presented as median TCID50/ml for each regimen.

Warimwe et al.

Warimwe et al. Virology Journal 2013 10:349   doi:10.1186/1743-422X-10-349

Open Data